Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

All releases
  • Regulatory Releases
  • Press Releases
2022
  • 2023
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Regulatory
December 28, 2022

Vivesto announces Erik Kinnman to take up CEO position in January

Regulatory
November 30, 2022

Vivesto announces that Christer Nordstedt will remain as acting CEO during a transition period

Regulatory
November 21, 2022

Vivesto appoints Erik Kinnman as CEO

Regulatory
November 21, 2022

Nomination Committee appointed for the 2023 Annual General Meeting in Vivesto

Regulatory
November 17, 2022

Interim report for the period January 1, 2022 – September 30, 2022

Non Regulatory
November 11, 2022

Invitation to presentation of Vivesto’s Q3 report 2022 on November 17

Regulatory
November 3, 2022

Christer Nordstedt resigns as acting CEO of Vivesto

Regulatory
August 25, 2022

Interim report for the period January 1, 2022 – June 30, 2022

Non Regulatory
August 18, 2022

Invitation to presentation of Vivesto’s Q2 report 2022 on August 25

Non Regulatory
August 15, 2022

Vivesto notes the launch of Apealea® in Germany by Inceptua

Regulatory
July 21, 2022

Vivesto appoints Christer Nordstedt as acting CEO

Regulatory
July 5, 2022

Vivesto winds down its activities in Russia

Regulatory
June 30, 2022

Vivesto appoints Robert Maiorana as acting CFO

Regulatory
June 13, 2022

Vivesto and CEO Francois Martelet have agreed on ending the employment relationship

Regulatory
May 25, 2022

Report from Annual General Meeting in Vivesto AB

Regulatory
May 25, 2022

Interim report for the period January 1, 2022 – March 31, 2022

Non Regulatory
May 18, 2022

Invitation to presentation of Vivesto’s Q1 report 2022 on May 25

Regulatory
April 29, 2022

New number of shares and votes in Vivesto

Regulatory
April 28, 2022

Correction: Vivesto publishes Annual Report for 2021

Regulatory
April 28, 2022

Vivesto publishes Annual Report for 2021

Regulatory
April 25, 2022

Notice of Annual General Meeting in Vivesto AB

Regulatory
April 19, 2022

The Nomination Committee of Vivesto proposes election of new Board members and new Chairman of the Board

Non Regulatory
April 19, 2022

Vivesto signs agreement with leading US CRO to evaluate anti-cancer drug formulations using its proprietary drug delivery platforms

Non Regulatory
April 11, 2022

Vivesto appoints Daniel Tesfa, M.D., PhD as Chief Medical Officer

Regulatory
March 31, 2022

New number of shares and votes in Vivesto

Non Regulatory
March 28, 2022

Oasmia announces completion of name change to Vivesto AB

Regulatory
March 25, 2022

FINAL RESULT OF OASMIA’S RIGHTS ISSUE

Regulatory
March 24, 2022

PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE

Non Regulatory
March 21, 2022

Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil

Non Regulatory
March 17, 2022

Oasmia expands R&D ability with planned laboratory upgrade

Non Regulatory
March 7, 2022

Oasmia to present at Aktiedagen Stockholm on March 14

Non Regulatory
March 7, 2022

Oasmia expands the intellectual property portfolio of its core technology platform in key territories

Regulatory
March 3, 2022

Oasmia announces CFO Fredrik Järrsten to step down later this year

Regulatory
March 3, 2022

OASMIA PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE

Regulatory
February 24, 2022

Year-end report January 1, 2021 – December 31, 2021

Non Regulatory
February 23, 2022

Update on Progress of SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar in Advanced Prostate Cancer

Regulatory
February 21, 2022

Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB

Non Regulatory
February 16, 2022

Invitation to presentation of Oasmia’s year-end report 2021 on February 24

Non Regulatory
January 24, 2022

Oasmia announces progress on the development of its next generation XR-18 drug delivery technology

Regulatory
January 19, 2022

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB

Non Regulatory
January 19, 2022

Oasmia announces intention to change its name to Vivesto

Regulatory
January 19, 2022

OASMIA RESOLVES ON A FULLY SECURED RIGHTS ISSUE OF APPROXIMATELY SEK 151 MILLION

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com